Alpharma Pain Franchise Adds Durect’s Eladur
This article was originally published in The Pink Sheet Daily
Executive Summary
Alpharma will pay Durect $20 million upfront for rights to the transdermal bupivacaine patch in development for post-herpetic neuralgia pain.